Lord, Abbett & Co
VTYX

Lord, Abbett & Co’s Ventyx Biosciences VTYX Stock Holding History

Lord, Abbett & Co’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,729,464
Closed -$60.1M – 592
2023
Q3 		$60.1M Sell
1,729,464
-587,711
-25% -$20.3M 0.22% 128
2023
Q2 		$76M Buy
2,317,175
+998,782
+76% +$34.4M 0.26% 116
2023
Q1 		$44.2M Sell
1,318,393
-525,014
-28% -$20.4M 0.16% 204
2022
Q4 		$60.4M Buy
1,843,407
+105,629
+6% +$3.13M 0.22% 125
2022
Q3 		$60.7M Buy
+1,737,778
New +$38.5M 0.22% 124

Other funds holding VTYX

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Lord, Abbett & Co's VTYX Position: Q4 2023 in Review

Lord, Abbett & Co sold out of Ventyx Biosciences (VTYX) in Q4 2023, closing a stake of 1,729,464 shares — an estimated $60.1M sold.

Lord, Abbett & Co first reported a position in VTYX in Q3 2022 and held it in 5 quarters. The position peaked at $76M in Q2 2023. 121 funds tracked by Wall St. Rank hold VTYX as of Q4 2023.

  • Lord, Abbett & Co reported no remaining Ventyx Biosciences position as of Q4 2023 after selling out during the quarter.
  • Lord, Abbett & Co sold 1,729,464 Ventyx Biosciences shares in Q4 2023, an estimated $60.1M.
  • Lord, Abbett & Co first reported a position in Ventyx Biosciences in Q3 2022 and held it in 5 quarters.
  • Lord, Abbett & Co's Ventyx Biosciences position peaked at $76M in Q2 2023.
  • 121 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q4 2023.

Based on Lord, Abbett & Co's 13F filing for Q4 2023, filed 12 Feb 2024.